A Prospective, Comparative, Active-controlled, Randomized, Open-label, Multicenter Study to Compare the Safety and Efficacy of Teriparatide of Enzene Biosciences Ltd. versus Forteo of Eli Lilly in the Treatment of Postmenopausal Osteoporosis
Latest Information Update: 21 Jan 2020
At a glance
- Drugs Teriparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Alkem Laboratories; Enzene Biosciences
- 10 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 12 Nov 2018 New trial record